• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Life Sciences | News, Analysis, Insights - HIT Consultant

Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI

by Fred Pennic 03/14/2024 Leave a Comment

Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI

What You Should Know: - Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group. - The company plans to use this round of funding to refine its technology to fortify its extensive collection of training and validation datasets, crucial for robust AI models, deliver results even faster, and expand its scientific and commercial
Read More

Pi Health Secures $30M to Democratize Cancer Clinical Trials

by Fred Pennic 03/14/2024 Leave a Comment

Pi Health Secures $30M to Democratize Cancer Clinical Trials

What You Should Know: - Pi Health, a newly independent oncology-focused clinical research company raises $30M in Series A funding led by  AlleyCorp and Obvious Ventures, with additional investments from Invus Capital and leaders in oncology from across the globe. - The company, previously incubated by BeiGene (NASDAQ: BGNE), aims to revolutionize access to innovative cancer treatments through its technology platform and global network of clinical trial sites. Less Than 8% of
Read More

Zetaris Unveils AI Studio for Disease Detection and Diagnosis

by Syed Hamza Sohail 03/14/2024 Leave a Comment

Zetaris Unveils AI Studio for Disease Detection and Diagnosis

What You Should Know: Zetaris, the provider of the AI-Powered Lakehouse, today unveils its game changing AI studio designed specifically for healthcare and life science professionals at the HIMSS Global Conference in Orlando on March 11-15, 2024.The Zetaris platform enables healthcare and life science professionals to develop life-saving patient outcomes enabled by data-driven AI clinical applications. Empowering Healthcare Excellence: Zetaris Unveils Next-Generation AI Studio for
Read More

HIMSS24: Google Cloud Unveils New Generative AI Solutions for Healthcare and Life Sciences

by Fred Pennic 03/12/2024 Leave a Comment

HIMSS24: Google Cloud Unveils New Generative AI Solutions for Healthcare and Life Sciences

What You Should Know: - At HIMSS24, Google Cloud announced a suite of new generative AI solutions designed to address key challenges faced by healthcare and life sciences organizations. - These solutions focus on improving interoperability, building a strong data foundation, and deploying generative AI (gen AI) tools to enhance patient outcomes. Unlocking Gen AI to Improve Healthcare Efficiency The healthcare industry is grappling with rising administrative costs, clinician burnout,
Read More

Israeli Life Science Industry Shows Resilience Despite Funding Slowdown

by Fred Pennic 03/11/2024 Leave a Comment

Israeli Life Science Industry Shows Resilience Despite Funding Slowdown

What You Should Know: - The Israel Advanced Technologies Institute (IATI), in partnership with PwC and the Israel Innovation Authority, unveiled its annual Life Science Industry report at the MIXiii Health-Tech.IL conference. - The report underlines the Israeli life sciences sector's resilience, unity, and determination to keep operating, innovating, and delivering crucial solutions. While acknowledging the current challenges, the research underscores the importance of continued support
Read More

Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery

by Fred Pennic 03/10/2024 Leave a Comment

Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery

What You Should Know: - Lexaria Bioscience Corp. is pushing the boundaries of oral drug delivery with their latest clinical trial. - The company announced they have contracted a research organization (CRO) to conduct a second human pilot study on their DehydraTECH-powered glucagon-like peptide-1 (GLP-1) treatment. GLP-1 Challenges and Lexaria's Solution GLP-1 drugs, like semaglutide, are currently delivered through injections or tablets. However, these methods have limitations.
Read More

Panacea Launches Whole Exome Sequencing

by Syed Hamza Sohail 03/06/2024 Leave a Comment

Panacea, Launches Whole Exome Sequencing

What You Should Know: - Panacea, the genetic health services provider, announces nationwide commercial availability, enabling consumers to access potentially life-saving testing without doctor visits or insurance approval. - Offering whole exome sequencing, Panacea conducts in-depth analysis of every human gene, aiding in the identification of disease-driving mutations for proactive disease management. - With nearly half of Americans facing cancer risk, approximately 20 million
Read More

ArteraAI’s Prostate Test Earns Recognition in NCCN Guidelines for Prostate Cancer

by Fred Pennic 03/04/2024 Leave a Comment

ArteraAI's Prostate Test Earns Recognition in NCCN Guidelines for Prostate Cancer

What You Should Know: - ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. - This marks a major milestone for ArteraAI, solidifying its position at the forefront of AI-driven oncology and personalized patient care.   A First for AI-powered Testing The ArteraAI Prostate Test is the
Read More

Absci Announces $75M Public Offering to Fuel AI Drug Creation

by Fred Pennic 02/28/2024 Leave a Comment

Absci Announces $75M Public Offering to Fuel AI Drug Creation

What You Should Know: - Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock. - This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes. Offering Details Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More

Veradigm Acquires ScienceIO for $140M in Cash to Accelerate AI Innovation in Healthcare

by Fred Pennic 02/27/2024 Leave a Comment

Veradigm Acquires ScienceIO for $140M in Cash to Accelerate AI Innovation in Healthcare

What You Should Know: - Veradigm Inc. (NASDAQ: MDRX), a provider of healthcare data and technology solutions, announced an agreement to acquire ScienceIO, a leader in healthcare AI platform and foundation models. - The acquisition is valued at $140 million in cash, with $44 million deferred and payable in installments over three years. Veradigm will fund the transaction entirely from existing cash reserves. Strategic Acquisition to Enhance AI Capabilities This acquisition signifies
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 29
  • Go to page 30
  • Go to page 31
  • Go to page 32
  • Go to page 33
  • Interim pages omitted …
  • Go to page 90
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |